Optogenetic gene therapy holds great promise for healing blindness. Hulliger et al have developed a new promoter that effectively targets human ON bipolar cells. This is an important step towards clinical applications of optogenetic gene therapy for restoring vision.

Nogo-A, an inhibitor of neural growth, prevents regeneration after injury. Blocking of Nogo-A aides recovery, also in the visual system after retinal damage. Baya Mdzomba show with our OptoDrum that visual behavior benefits from Nogo-A neutralization after retinal damage typically found in diabetic retinopathy or glaucoma.